1: Qi H, Zhao S, Fu H, Wen J, Jia X. Enhancement of ascomycin production in Streptomyces hygroscopicus var. ascomyceticus by combining resin HP20 addition and metabolic profiling analysis. J Ind Microbiol Biotechnol. 2014 Sep;41(9):1365-74. doi: 10.1007/s10295-014-1473-9. Epub 2014 Jun 26. PubMed PMID: 24965502.
2: Bulusu MA, Baumann K, Stuetz A. Chemistry of the immunomodulatory macrolide ascomycin and related analogues. Prog Chem Org Nat Prod. 2011;94:59-126. doi: 10.1007/978-3-7091-0748-5_2. Review. PubMed PMID: 21833838.
3: Sierra-Paredes G, Sierra-Marcuño G. Ascomycin and FK506: pharmacology and therapeutic potential as anticonvulsants and neuroprotectants. CNS Neurosci Ther. 2008 Spring;14(1):36-46. doi: 10.1111/j.1527-3458.2008.00036.x. Review. PubMed PMID: 18482098.
4: Vázquez-López A, Sierra-Paredes G, Sierra-Marcuño G. Anticonvulsant effect of the calcineurin inhibitor ascomycin on seizures induced by picrotoxin microperfusion in the rat hippocampus. Pharmacol Biochem Behav. 2006 Jul;84(3):511-6. Epub 2006 Jul 26. PubMed PMID: 16872668.
5: Napoli KL. Organic solvents compromise performance of internal standard (ascomycin) in proficiency testing of mass spectrometry-based assays for tacrolimus. Clin Chem. 2006 Apr;52(4):765-6. PubMed PMID: 16595827.
6: Junker J, Maier W, Lindel T, Köck M. Computer-assisted constitutional assignment of large molecules: COCON analysis of ascomycin. Org Lett. 1999 Sep 9;1(5):737-40. PubMed PMID: 16118875.
7: Monaghan P, Fardis M, Revill WP, Bell A. Antimalarial effects of macrolactones related to FK520 (ascomycin) are independent of the immunosuppressive properties of the compounds. J Infect Dis. 2005 Apr 15;191(8):1342-9. Epub 2005 Mar 4. PubMed PMID: 15776382.
8: Revill WP, Voda J, Reeves CR, Chung L, Schirmer A, Ashley G, Carney JR, Fardis M, Carreras CW, Zhou Y, Feng L, Tucker E, Robinson D, Gold BG. Genetically engineered analogs of ascomycin for nerve regeneration. J Pharmacol Exp Ther. 2002 Sep;302(3):1278-85. PubMed PMID: 12183690.
9: Uchida T, Fujimori F, Nagata N. Identification of genes coding enzymes for ascomycin tetra-hydropyranose ring formation. Int J Mol Med. 2002 Feb;9(2):141-5. PubMed PMID: 11786924.
10: Reeves CD, Chung LM, Liu Y, Xue Q, Carney JR, Revill WP, Katz L. A new substrate specificity for acyl transferase domains of the ascomycin polyketide synthase in Streptomyces hygroscopicus. J Biol Chem. 2002 Mar 15;277(11):9155-9. Epub 2002 Jan 10. PubMed PMID: 11786554.
11: Song Z, DeMarco A, Zhao M, Corley EG, Thompson AS, McNamara J, Li Y, Rieger D, Sohar P, Mathre DJ, Tschaen DM, Reamer RA, Huntington MF, Ho GJ, Tsay FR, Emerson K, Shuman R, Grabowski EJ, Reider PJ. Highly Chemoselective Trichloroacetimidate-Mediated Alkylation of Ascomycin: A Convergent, Practical Synthesis of the Immunosuppressant L-733,725. J Org Chem. 1999 Mar 19;64(6):1859-1867. PubMed PMID: 11674275.
12: Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M, Henz BM. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol. 2001 Aug;108(2):275-80. PubMed PMID: 11496246.
13: Griffiths CE. Ascomycin: an advance in the management of atopic dermatitis. Br J Dermatol. 2001 Apr;144(4):679-81. PubMed PMID: 11298524.
14: Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol. 2001 Mar;144(3):507-13. PubMed PMID: 11260007.
15: Küsters E, Heuer C, Wieckhusen D. Purification of an ascomycin derivative with simulated moving bed chromatography. A case study. J Chromatogr A. 2000 Apr 7;874(2):155-65. PubMed PMID: 10817355.
16: Wiedeman PE, Fesik SW, Petros AM, Nettesheim DG, Mollison KW, Lane BC, Or YS, Luly JR. Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12. J Med Chem. 1999 Oct 21;42(21):4456-61. PubMed PMID: 10543889.
17: Armstrong HM, Wong F, Holmes MA, Sinclair PJ, Goulet MT, Dumont FJ, Staruch MJ, Koprak S, Peterson LB, Rosa R, Wilusz MB, Wiederrecht GJ, Cryan JG, Wyvratt MJ, Parsons WH. Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicity. Bioorg Med Chem Lett. 1999 Jul 19;9(14):2089-94. PubMed PMID: 10450987.
18: Goulet MT, Sinclair PJ, Wong F, Staruch MJ, Dumont FJ, Cryan JG, Wiederrecht GJ, Wyvratt MJ, Parsons WH. C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study. Bioorg Med Chem Lett. 1999 Jul 19;9(14):2085-8. PubMed PMID: 10450986.
19: Becker JW, Rotonda J, Cryan JG, Martin M, Parsons WH, Sinclair PJ, Wiederrecht G, Wong F. 32-Indolyl ether derivatives of ascomycin: three-dimensional structures of complexes with FK506-binding protein. J Med Chem. 1999 Jul 29;42(15):2798-804. PubMed PMID: 10425089.
20: Mollison KW, Fey TA, Gauvin DM, Sheets MP, Smith ML, Pong M, Krause R, Miller L, Or YS, Kawai M, Wagner R, Wiedeman PE, Clark RF, Gunawardana IW, Rhoades TA, Henry CL, Tu NP, BaMaung NY, Kopecka H, Liu L, Xie Q, Lane BC, Trevillyan JM, Marsh K, Luly JR, et al. Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Curr Pharm Des. 1998 Oct;4(5):367-79. Review. PubMed PMID: 10197049.